BCAL Diagnostics Ltd
BDX
Company Profile
Business description
BCAL Diagnostics Ltd is an Australian health care company engaged in early cancer detection. BCAL launched its first test, BREASTESTplus, as a rule-out test designed to be used in the clinical evaluation of breast disease for women with dense breasts. BREASTESTplus is a simple, non-invasive blood test used in conjunction with mammography to improve screening and diagnostic outcomes for breast health in women. BCAL holds an exclusive license with ClearNote Health Inc., a U.S-based precision diagnostics company, for the sale and distribution of Avantect Pancreatic, Avantect Ovarian and Avantect multi-cancer blood tests in Australia and New Zealand.
Contact
GPO Box Q128
Queen Victoria Building
SydneyNSW1230
AUSSector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
Employees
Stocks News & Analysis
stocks
An undervalued stock to buy that even Warren Buffett likes
Trading at an 18% discount, this wide-moat stock is a rare find.
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,845.60 | 51.40 | -0.58% |
| CAC 40 | 8,070.73 | 10.70 | -0.13% |
| DAX 40 | 25,384.48 | 117.95 | 0.47% |
| Dow JONES (US) | 51,524.15 | 174.17 | 0.34% |
| FTSE 100 | 10,689.58 | 9.59 | 0.09% |
| HKSE | 24,510.09 | 251.04 | -1.01% |
| NASDAQ | 26,995.55 | 56.18 | 0.21% |
| Nikkei 225 | 66,364.20 | 850.21 | 1.30% |
| NZX 50 Index | 13,811.11 | 13.72 | -0.10% |
| S&P 500 | 7,718.96 | 14.83 | 0.19% |
| S&P/ASX 200 | 8,665.00 | 37.00 | -0.43% |
| SSE Composite Index | 3,888.37 | 48.15 | -1.22% |